NASDAQ:AGRX - Agile Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.60
  • Forecasted Upside: 204.96 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.82
▲ +0.1 (3.68%)
1 month | 3 months | 12 months
Get New Agile Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.60
▲ +204.96% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Agile Therapeutics in the last 3 months. The average price target is $8.60, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 204.96% upside from the last price of $2.82.
Buy
The current consensus among 6 investment analysts is to buy stock in Agile Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/2/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020Royal Bank of CanadaReiterated RatingBuy$8.00Medium
i
11/13/2020OppenheimerReiterated RatingBuy$12.00Low
i
9/25/2020William BlairReiterated RatingBuyLow
i
9/9/2020Maxim GroupReiterated RatingBuy$8.00Low
i
8/12/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by O. Livnat at HC Wainwright
3/25/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
i
3/20/2020HC WainwrightLower Price TargetBuy$7.00 ➝ $6.00High
i
2/19/2020Janney Montgomery ScottBoost Price TargetBuy ➝ Fair Value$4.00 ➝ $9.00High
i
2/18/2020HC WainwrightBoost Price TargetBuy$5.00 ➝ $7.00Medium
i
2/18/2020Royal Bank of CanadaBoost Price TargetOutperform$5.00 ➝ $8.00Low
i
11/1/2019Maxim GroupReiterated RatingBuyHigh
i
Rating by Jason McCarthy at Maxim Group
10/31/2019William BlairUpgradeMarket Perform ➝ OutperformN/A
i
10/31/2019Royal Bank of CanadaBoost Price TargetOutperform$5.00Low
i
10/11/2019Maxim GroupSet Price TargetBuy$3.00Low
i
Rating by Jason McCarthy at Maxim Group
6/10/2019Maxim GroupSet Price TargetBuy$3.00Medium
i
Rating by Jason McCarthy at Maxim Group
6/6/2019OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00High
i
5/17/2019Maxim GroupSet Price TargetBuy$3.00Low
i
Rating by Caroline Palomeque at Maxim Group
4/12/2019Janney Montgomery ScottInitiated CoverageBuy$4.00Low
i
2/11/2019Maxim GroupReiterated RatingBuy$3.00High
i
Rating by Caroline Palomeque at Maxim Group
1/11/2019HC WainwrightReiterated RatingBuy$4.00Medium
i
Rating by Oren Livnat at HC Wainwright
11/29/2018Maxim GroupInitiated CoverageBuy ➝ Buy$3.00High
i
Rating by Caroline Palomeque at Maxim Group
10/9/2018HC WainwrightSet Price TargetBuy$4.00High
i
Rating by Oren Livnat at HC Wainwright
5/21/2018Royal Bank of CanadaLower Price TargetOutperform$3.00High
i
5/21/2018HC WainwrightSet Price TargetBuy$4.00High
i
Rating by Oren Livnat at HC Wainwright
5/9/2018HC WainwrightSet Price TargetBuy$8.00Medium
i
Rating by Oren Livnat at HC Wainwright
3/14/2018Noble FinancialReiterated RatingBuyHigh
i
Rating by Caroline Palomeque at Noble Financial
3/13/2018HC WainwrightReiterated RatingBuy$8.00High
i
Rating by Oren Livnat at HC Wainwright
12/28/2017HC WainwrightSet Price TargetBuy$8.00Low
i
Rating by Oren Livnat at HC Wainwright
12/28/2017Noble FinancialReiterated RatingBuyLow
i
Rating by Caroline Palomeque at Noble Financial
12/28/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralLow
i
Rating by Ken Trbovich at Janney Montgomery Scott
12/26/2017William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by T. Lugo at William Blair
12/22/2017Noble FinancialReiterated RatingBuyHigh
i
Rating by Kumaraguru Raja at Noble Financial
12/22/2017Cantor FitzgeraldReiterated RatingBuy$5.00High
i
Rating by W. Tanner at Cantor Fitzgerald
12/22/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
i
12/22/2017HC WainwrightSet Price TargetBuy$8.00N/A
i
Rating by Oren Livnat at HC Wainwright
11/20/2017Cantor FitzgeraldReiterated RatingBuy$8.00N/A
i
Rating by W. Tanner at Cantor Fitzgerald
11/6/2017Cantor FitzgeraldReiterated RatingBuy$8.00N/A
i
Rating by W. Tanner at Cantor Fitzgerald
10/18/2017Royal Bank of CanadaReiterated RatingBuy$10.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/12/2017HC WainwrightSet Price TargetBuy$10.00N/A
i
Rating by O. Livnat at HC Wainwright
10/2/2017HC WainwrightReiterated RatingBuy ➝ Buy$10.00High
i
Rating by C. Davis at HC Wainwright
9/21/2017Cantor FitzgeraldReiterated RatingOverweight$8.00High
i
Rating by Chiara Russo at Cantor Fitzgerald
9/14/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
9/7/2017Janney Montgomery ScottReiterated RatingBuy$13.00High
i
8/24/2017Janney Montgomery ScottReiterated RatingBuy$15.00 ➝ $13.00Low
i
7/30/2017Noble FinancialReiterated RatingBuyMedium
i
Rating by Kumaraguru Raja at Noble Financial
7/21/2017Janney Montgomery ScottReiterated RatingBuy$15.00Low
i
7/19/2017HC WainwrightInitiated CoverageBuy ➝ Buy$10.00High
i
Rating by C. Davis at HC Wainwright
7/16/2017Royal Bank of CanadaSet Price TargetBuy$8.00High
i
6/14/2017Noble FinancialReiterated RatingBuyLow
i
5/8/2017Cantor FitzgeraldReiterated RatingBuy$9.00Medium
i
Rating by Chiara Russo at Cantor Fitzgerald
4/4/2017Cantor FitzgeraldBoost Price TargetOverweight$7.00 ➝ $8.00High
i
Rating by Chiara Russo at Cantor Fitzgerald
3/13/2017Noble FinancialReiterated RatingBuyLow
i
3/11/2017FBR & CoSet Price TargetBuy$10.00Low
i
Rating by Edward White at FBR & Co
3/9/2017Cantor FitzgeraldSet Price TargetBuy$7.00Low
i
Rating by Chiara Russo at Cantor Fitzgerald
1/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/A
i
1/5/2017Royal Bank of CanadaReiterated RatingOutperform$15.00 ➝ $8.00N/A
i
1/5/2017Janney Montgomery ScottReiterated RatingBuy$15.00N/A
i
1/4/2017Cantor FitzgeraldSet Price TargetBuy$7.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
1/4/2017FBR & CoSet Price TargetBuy$10.00N/A
i
Rating by Edward White at FBR & Co
12/1/2016Cantor FitzgeraldSet Price TargetBuy$18.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
11/8/2016FBR & CoReiterated RatingBuy$16.00N/A
i
Rating by Edward White at FBR & Co
8/9/2016Noble FinancialReiterated RatingBuy$15.00N/A
i
7/8/2016Noble FinancialReiterated RatingBuy$15.00N/A
i
6/17/2016FBR & CoReiterated RatingBuyN/A
i
Rating by Edward White at FBR & Co
6/2/2016FBR & CoReiterated RatingBuyN/A
i
Rating by Edward White at FBR & Co
5/31/2016Cantor FitzgeraldReiterated RatingBuyN/A
i
Rating by Chiara Russo at Cantor Fitzgerald
5/10/2016FBR & CoReiterated RatingBuy$17.00N/A
i
Rating by Edward White at FBR & Co
5/10/2016Cantor FitzgeraldReiterated RatingBuy$18.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
3/10/2016Cantor FitzgeraldReiterated RatingBuy$18.00N/A
i
Rating by Chiara Russo at Cantor Fitzgerald
2/2/2016Royal Bank of CanadaReiterated RatingOutperform$13.00 ➝ $15.00N/A
i
1/28/2016FBR & CoReiterated RatingOutperform$17.00N/A
i
1/8/2016Cantor FitzgeraldInitiated CoverageBuy$18.00N/A
i
12/30/2015Noble FinancialInitiated CoverageBuy ➝ Buy$16.00N/A
i
(Data available from 11/25/2015 forward)
Agile Therapeutics logo
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $2.82
$2.68
$2.83

50 Day Range

MA: $2.97
$2.72
$3.25

52 Week Range

Now: $2.82
$1.35
$4.77

Volume

1,330,908 shs

Average Volume

2,220,000 shs

Market Capitalization

$246.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42